Loading
A phase 3 trial of Petosemtamab in head and neck squamous cell carcinoma, run by Merus B.V., active and no longer recruiting.
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2) is a phase 3 interventional study registered as NCT06496178 by Merus B.V., with 621 participants enrolled, started 2024-06-25 and due to reach its primary completion in 2028-02. Interventions recorded: Petosemtamab, Investigator's Choice, Investigator's Choice, Investigator's Choice. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Shares Petosemtamab, Genmab, Bispecific antibodies, Head and neck squamous cell carcinoma.
Shares Petosemtamab, Genmab, Recurrent or metastatic head and neck squamous cell carcinoma, Bispecific antibodies.
Shares Petosemtamab, Genmab, Bispecific antibodies.
Shares Petosemtamab, Genmab, Bispecific antibodies.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Bispecific antibodies, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.